Serum Institute Seeks DGCI Approval To Roll Out Covovax Vaccine

Mumbai: As India is buckling up to face possible COVID-19, one of the premier drug manufacturing companies–Serum Institute of India (SII) has sought the DCGI’s approval for market authorisation of its COVID-19 vaccine- Covovax.

According to officials, the drug manufacturing unit has sought clearance to be administered to those who have been administered two doses of Covishield or Covaxin.

It may be noted that Covovax is the indigenous version of a Covid vaccine developed by Novovax Inc and manufactured under a licence of the Serum Institute of India.

In terms of formulation, it is a recombinant protein vaccine that uses spike proteins to familiarise the human body on how to develop immunity against SARS-CoV-2.